• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email
    SC 13G/A 1 caba2.htm 13G HTML File DOCUMENT TYPE SC 13G/A
    TEXT


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    Amendment # 1

    Name of Issuer: CABALETTA BIO INC
    _____________________________________________________
    Title of Class
    of Securities: Common Stock

    CUSIP Number: 12674W109

    1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON

    Prudential Financial, Inc. 22-3703799

    2.) MEMBER OF A GROUP: (a) N/A
    (b) N/A

    3) SEC USE ONLY:



    4) PLACE OF ORGANIZATION: New Jersey

    NUMBER OF SHARES BENEFICIALLY OWNED BY REPORTING PERSON WITH:

    5) Sole Voting Power: 2,810 See Exhibit A
    6) Shared Voting Power: 2,796,053 See Exhibit A
    7) Sole Dispositive Power: 2,810 See Exhibit A
    8) Shared Dispositive Power: 2,796,053 See Exhibit A

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED: 2,798,863 See Exhibit A

    10) AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES: Not Applicable

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 5.7 See Exhibit A

    12) TYPE OF REPORTING PERSON: HC

    ITEM 1(a). NAME OF ISSUER:

    CABALETTA BIO INC

    ITEM 1(b). ADDRESS OF ISSUER'S EXECUTIVE OFFICES:

    2929 ARCH STREET, SUITE 600 PHILADELPHIA, PA 19104

    ITEM 2(a). NAME OF PERSON FILING:

    Prudential Financial, Inc.

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    751 Broad Street
    Newark, New Jersey 07102-3777

    ITEM 2(c). CITIZENSHIP:

    New Jersey

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2(e). CUSIP NUMBER:

    12674W109

    ITEM 3. The Person filing this statement is a Parent Holding Company as
    defined in Section 240.13d-1(b)(1)(ii)(G) of the Securities Exchange
    Act of 1934.

    ITEM 4. OWNERSHIP:

    (a) Number of Shares
    Beneficially Owned: 2,798,863 See Exhibit A


    (b) Percent of Class: 5.7


    (c) Powers                No. Of Shares
    ----------- --------------------
    Sole power to vote or 2,810 See Exhibit A to direct the vote
    Shared power to vote or 2,796,053 See Exhibit A to direct the vote
    Sole power to dispose or 2,810 See Exhibit A to direct disposition
    Shared power to dispose 2,796,053 See Exhibit A or to direct disposition

    ITEM 5. OWNERSHIP OF 5% OR LESS OF A CLASS:

    Not Applicable

    ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF
    ANOTHER PERSON:

    Our clients may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities which are the subject of this filing.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE
    SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
    REPORTED ON BY THE ULTIMATE PARENT COMPANY:

    See Exhibit A

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
    MEMBERS OF THE GROUP:

    Not Applicable

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

    Not Applicable

    ITEM 10. CERTIFICATION:

    By signing below, Prudential Financial, Inc. certifies that, to the best of its
    knowledge and belief, the securities referred to above were acquired
    and are held in the ordinary course of business and were not acquired
    and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction
    having that purpose or effect.


    The filing of this statement should not be construed as an admission that
    Prudential Financial, Inc. is, for purposes of Sections 13 or 16 of the Securities
    Exchange Act of 1934, the beneficial owner of such shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief,
    Prudential Financial, Inc. certifies that the information set forth in this
    statement is true, complete and correct.

    PRUDENTIAL FINANCIAL, INC.

    By:RICHARD BAKER
    Second Vice President

    Date:12-5-2024
    As of:11-30-2024

    Exhibit A
    --------------

    ITEM 4. OWNERSHIP:

      Through its parent/subsidiary relationship, Prudential Financial, Inc. may
      be deemed the beneficial owner of the same securities as the Item 7 listed
      subsidiaries and may have direct or indirect voting and/or investment
      discretion over 2,798,863 shares.
      

    These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Prudential Financial, Inc. is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares.




    ITEM 7. IDENTIFICATION/CLASSIFICATION:

    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names:
    

    
    
    Subsidiaries Number of Shares Percentage
    The Prudential Insurance Company of America IC 0 0.0
    Jennison Associates LLC IA 2,512,053 5.1
    PGIM, Inc. IA 284,000 0.6
    PGIM Quantitative Solutions LLC IA 2,810 0.0
    PRUCO Securities, LLC IA 0 0.0





    Get the next $CABA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Cabaletta Bio Inc.

      PRE 14A - Cabaletta Bio, Inc. (0001759138) (Filer)

      4/30/25 8:00:18 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cabaletta Bio Inc.

      EFFECT - Cabaletta Bio, Inc. (0001759138) (Filer)

      4/1/25 12:15:12 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Cabaletta Bio Inc.

      S-8 - Cabaletta Bio, Inc. (0001759138) (Filer)

      3/31/25 8:33:10 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Financials

    Live finance-specific insights

    See more
    • Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

      – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula

      11/18/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

      – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash

      11/14/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

      – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu

      6/14/24 2:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President, Science & Tech. Binder Gwendolyn

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      3/4/25 4:55:25 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Marda Anup

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      3/4/25 4:52:42 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel Gerard Michael

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      3/4/25 4:49:10 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cabaletta Bio downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

      12/20/24 7:29:05 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

      12/19/24 7:31:17 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Cabaletta Bio with a new price target

      UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

      10/10/24 7:27:43 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

      – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20

      7/24/23 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

      PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati

      9/7/21 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/6/24 4:05:57 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 4:50:19 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 3:36:55 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage bi

      3/31/25 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

      Technology Adoption Program (TAP) program success demonstrates the ability of Cellares' IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio's clinical-stage CAR T program to treat patients with autoimmune diseases. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel, (rese-cel, previously known as CABA-201). Rese-cel is the lead clinical candidate in development by Cabaletta Bio, a biotechnology company focused on developing and launching the first curative targeted cell therapies desig

      3/19/25 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

      PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a clinical-stage b

      2/26/25 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care